Disintegration measures the time required for a tablet to break apart into smaller particles under specific mechanical agitation in a fluid medium. Monograph 0478 establishes clear maximum disintegration time limits based on tablet type: Typically within 15 minutes in water.

The European Pharmacopoeia (Ph. Eur.) Monograph 0478, (Compressi), defines the general quality, manufacturing, and testing standards for tablet preparations, including requirements for dissolution and mass uniformity. It specifies standards for various types, such as uncoated, coated, and gastro-resistant tablets, often requiring compliance with additional Ph. Eur. chapters. For the full text, see uspbpep.com

[Granulation / Blending] ──> [In-Process Mechanical Testing] ──> [Microbiological & Divisibility Quality Checks]

Weighing individual tablets to ensure they fall within strict percentage deviations.

Many commercial tablets feature break-marks (notches) to support dose flexibility or ease of swallowing. Monograph 0478 mandates strict compliance regarding the uniformity of mass for subdivided parts. Manufacturers must demonstrate that splitting the tablet manually or with a splitter yields highly predictable, equal fractions of the therapeutic dose.

The Ph. Eur. monograph for tablets (0478) plays a critical role in ensuring the quality of tablet products in Europe. By following this monograph, manufacturers can ensure that their products meet the required standards for quality, purity, and strength. The monograph also provides a common language and set of standards for regulatory authorities, manufacturers, and control laboratories to evaluate the quality of tablet products.

The monograph references strict testing methods to ensure that the variance between tablets is statistically insignificant. This is where the "mass variation" test meets the "content uniformity" test. If a tablet contains a tiny amount of potent API (like a hormone or an opioid), weighing the tablet isn't enough; chemists must assay the content of individual units. 0478 dictates when to use which method, ensuring that a patient never receives a "super-potent" or "sub-potent" dose.

According to Ph. Eur. 0478, tablets are containing one or more active substances. They are typically obtained by compressing uniform volumes of particles or aggregates, such as granules.

: To facilitate the manufacturing process.

: To provide bulk and cohesive properties.

💡 Monograph 0478 is the blueprint that ensures a tablet is more than just compressed powder—it is a sophisticated delivery system designed for precision and patient safety.

Monograph 0478 also outlines expectations for the manufacturing process. It emphasizes that the production method must be validated to ensure: Minimal risk of microbial contamination. Mechanical strength suitable for packaging and transport. Consistency in the release of active ingredients.

According to the monograph, tablets are solid preparations, each containing a single dose of one or more active substances. They are primarily obtained by compressing uniform volumes of particles but can also be manufactured via extrusion, moulding, or freeze-drying (lyophilisation).